- $138.44bn
- $190.12bn
- $62.58bn
US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Brief: Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration With Pfizer
Brief: Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
Brief: Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program After Strong Positive Phase 2 Results
Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial
US states reject anti-vaccine bills as public health groups fight MAHA
Brief: Mubadala Investment Dissolves Share Stake In Pfizer, Ford Motor, Walt Disney
Advisory: Incorrect alert on Mubadala's stake in Citigroup withdrawn
Bain-backed Tanabe Pharma targets three new drug launches a year in Japan
U.S. STOCKS ON THE MOVE -Fervo, Sensata Technologies, Akamai
U.S. STOCKS ON THE MOVE-Chipmakers, Dynatrace, Alibaba
U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings
U.S. STOCKS ON THE MOVE-Orla Mining, Personalis, Eos Energy
Brief: European Commission Approves Pfizer’S Hympavzi For The Treatment Of Adults And Adolescents With Hemophilia A Or B With Inhibitors
Pfizer's India unit drops on quarterly profit fall
Replimune, uniQure rise; FDA commissioner Makary plans to resign
Rigel rises on licensing deal for Pfizer-Arvinas breast cancer drug
Rigel rises on licensing deal for Pfizer-Arvinas breast cancer drug